Human papillomavirus (HPV) is an important etiological factor in oropharyngeal squamous cell carcinoma (SCC). Compared to HPV-negative tumors, HPV-positive oropharyngeal SCC has shown a better response to nonsurgical treatments. In this study, we determined the dose-modifying factors for HPV-positive tumors with single-dose irradiation, with or without low radiosensitizing doses of cisplatin.In vitro, we determined an increased radiosensitivity of HPV-positive SCC, which might be a consequence of HPV-induced changes in the cell cycle regulation and DNA damage response, leading to increased cell death. Additionally, compared to HPV-negative tumors, 30% higher radiosensitivity of HPV-positive tumors was determined by tumor growth delay monitoring in immunodeficient mice in vivo. Concurrent cisplatin treatment had an additive effect in both HPV-negative and HPV-positive tumors, resulting in 20% better response in HPV-positive tumors than in HPV-negative tumors.
How to translate text using browser tools
13 April 2018
Dose-Modifying Factor of Radiation Therapy with Concurrent Cisplatin Treatment in HPV-Positive Squamous Cell Carcinoma: A Preclinical Study
Ajda Prevc,
Simona Kranjc,
Maja Cemazar,
Vesna Todorovic,
Bojana Zegura,
Matjaz Novak,
Metka Filipic,
Margareta Strojan Flezar,
Irena Srebotnik Kirbis,
Ana Rotter,
Andreja Brozic,
Martina Niksic Zakelj,
Mario Poljak,
Lea Hosnjak,
Blaz Groselj,
Primoz Strojan,
Gregor Sersa
ACCESS THE FULL ARTICLE
Radiation Research
Vol. 189 • No. 6
June 2018
Vol. 189 • No. 6
June 2018
